Good afternoon, everyone. Thank you for standing by. Welcome to the CytomX Therapeutics Second Quarter 2024 Financial Results Call. Please be advised that today's call is being recorded. I would now like to hand the call over to your host for today, Chris Ogden, CytomX's Chief Financial Officer. Please go ahead. Thank you. Good afternoon, and thank you for joining us. Before we begin, I would like to remind everyone that during this call, we will be making forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict and many of which are outside of our control. Important risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. We undertake no obligations to update any forward-looking statements, whether as a result of new information, future developments, or otherwise. Earlier this afternoon, we issued a press release that includes a summary of our second quarter 2024 financial results and highlights recent progress at CytomX. We encourage everyone to read today's press release and the associated materials, which have been filed with the SEC. Additionally, the press release, recording of this call, and our SEC filings can be found under the Investors and News section of our website. With me on the call today is Dr. Sean McCarthy, CytomX's Chief Executive Officer and Chairman. Sean will provide an update on the company's progress and pipeline before I cover the financials for the quarter, and we open up the call for Q&A. With that, I'll now turn the call over to Sean. Thanks, Chris, and good afternoon, everyone. We're delighted today to provide an update on our recent progress, which includes the continued development of CX-904 in phase 1 dose escalation and clinical study initiation for our newest wholly owned programs, CX-2051 and CX-801. CytomX Probody therapeutic platform encompasses more than a decade of innovation in antibody masking and conditional activation, and it's designed to enable the clinical development of anticancer modalities directed against targets that would otherwise be undruggable or significantly limited by therapeutic window. CytomX currently has 15 active programs across our internal and partnered research and development activities, including three clinical-stage Probody therapeutics designed to address large patient populations. Based on our continued strong execution, CytomX is currently very well positioned to build value and make a meaningful difference for cancer patients. Let me dive right in and start with CX-904, our masked Probody T-cell engager targeting EGFR. Last quarter, we announced positive initial phase 1A clinical data for CX-904, which was an important first step in the clinical development of this program. EGFR is a very attractive target, given its broad expression across multiple tumor types and also its high level of clinical and commercial validation, with multiple approved small molecule and antibody therapies. CX-904 constitutes a novel therapeutic strategy that leverages EGFR as an address to direct T-cell-mediated killing to tumor cells via CD3 binding. EGFR CD3 has previously been considered an attractive but undruggable target combination because of the widespread expression of EGFR in normal tissues. In the absence of masking, we would expect an EGFR CD3 bispecific to be severely toxic and undevelopable, likely with high rates of severe skin rash and cytokine release syndrome. By using the CytomX Probody platform to mask both EGFR and CD3 binding domains, however, we are opening a therapeutic window for this target combination, and we've been very encouraged by our clinical findings reported to date. In May, we were delighted to release positive initial Phase 1A dose-escalation results for CX-904, achieving our early Phase 1 goals. In this first data release for CX-904, based on an April 16, 2024 data cutoff, we reported on 35 heavily pretreated patients with a median of 4 prior lines of therapy. The initial safety profile of CX-904 looks very encouraging, specifically in step-dosing cohorts up to a target dose of 10 milligrams. We did not see any cytokine release syndrome, and across all 35 patients treated with non-step and step dosing schedules, we saw only 1 grade 3 rash. In common with certain other T-cell engagers, we observed some musculoskeletal, skeletal events that were manageable, in part with tocilizumab prophylaxis. These early findings show that masking is effectively blunting CRS and other toxicities that would be expected for the corresponding unmasked EGFR CD3 T-cell engager. In the context of this emerging favorable safety profile, we also reported encouraging early signs of single-agent anticancer activity for CX-904. In 26 efficacy-evaluable patients treated at doses above 750 micrograms, we observed 8 measurable tumor reductions, including confirmed partial responses in 2 of 6 efficacy-evaluable patients with pancreatic ductal adenocarcinoma.... These initial findings are particularly encouraging because pancreatic cancer has not been shown historically to respond to immunotherapy or to EGFR antibodies. However, EGFR is expressed in more than 90% of pancreatic cancer patients, and our data suggests that CD3-mediated T-cell killing via EGFR binding can be effective in this cancer type. Moreover, there's also increasing evidence from others in the field that pancreatic cancer can be immune competent and mount a T-cell response. This is both based on progress with neoadjuvant vaccines and recent data from ASCO 2024 for a claudin 18.2 CD3 T-cell engager. In our view, our early CX-904 results in pancreatic cancer highlight exactly why CX-904 was designed, and they illustrate the power of antibody masking, opening a therapeutic window for an undruggable T-cell engager target and bringing a unique pharmacology to a cancer type of high incidence and significant unmet medical need. Indeed, pancreatic ductal adenocarcinoma is currently the third leading cause of cancer death in the US, and second-line treatments have response rates of less than 10% and only 2-3 months of progression-free survival, leaving a major need for new therapies. We are now accelerating enrollment in pancreatic cancer to further explore this signal, and in parallel, we're prioritizing enrollment in head and neck and non-small cell lung cancers, where we had not previously enrolled a meaningful number of patients in the initial dose escalation. We continue to enroll at multiple dose levels to further inform the selection of a recommended phase 1b dose or potentially doses. Our principal goal for the second half of the year is to generate data to enable strategic dialogue with our global development partner, Amgen, regarding potential initiation of CX-904 phase 1b expansions in select EGFR-expressing tumor types. We expect to provide a CX-904 program update by the end of 2024. Turning now to CX-2051, our wholly owned, first-in-class EpCAM-directed Probody ADC. EpCAM, or epithelial cell adhesion molecule, is a high-potential oncology target with high cell surface expression in many solid tumor types, and that has been implicated in many aspects of cancer biology. Anti-EpCAM therapeutic strategies have previously been translated into clinical activity, but to date, clinical success has been limited to local administration because EpCAM is present in most normal epithelial tissues. Efforts to generate systemically administered anti-EpCAM therapies have not been successful to date due to toxicities in epithelial tissues, including in the gastrointestinal tract. Our innovative drug candidate, CX-2051, is a masked ADC tailored to optimize the therapeutic window for EpCAM-expressing epithelial cancers by masking the antibody to reduce binding in normal tissues, but allowing activation in tumor tissue. We have armed the antibody with a cytotoxic payload based on camptothecin, a topoisomerase I inhibitor, which is a class of drug that has shown potent clinical anticancer activity in the ADC context for multiple targets, leading in recent years to dramatic advances for patients. CX-2051 has demonstrated a wide predicted therapeutic index in multiple preclinical models, including colorectal cancer, and like EGFR, discussed previously in the context of CX-904, CX-2051 could also potentially address large patient populations because EpCAM is highly expressed across many indications, including colorectal, lung, gastric, endometrial, pancreatic, and ovarian cancers. In April of this year, we treated our first patient in our phase 1 dose-escalation study of CX-2051, and we're now already enrolling into our third patient cohort. At this stage, enrollment is principally focused in colorectal cancer, where EpCAM expression is particularly high, and we're really looking forward to seeing what CX-2051 can do for patients. Based on this progress, we remain on track to share initial data for CX-2051 in the first half of 2025. Now turning to our third clinical program, CX-801, which is our dually masked interferon alpha-2b Probody cytokine. We're excited about CX-801 as a foundational immuno-oncology agent with potential for activity across multiple tumor types, including those that are insensitive to current immuno-oncology therapies. Interferon is a compelling and differentiated opportunity as a masked cytokine for two key reasons. First, the biology of interferon is unique in that it has been shown to directly kill tumor cells, and interferon also increases antigen presentation to activate T-cells, making it an ideal mechanism for combination with checkpoint inhibition. Secondly, as a previously approved cancer therapy, interferon has a high level of prior clinical validation, including as both a localized therapy and systemically when combined with PD-1. The use of interferon in its broader development as a systemic therapy has been limited, however, due to systemic toxicities. Our preclinical data for CX-801, most recently presented at SITC 2023, demonstrates synergy for our masked interferon alpha with PD-1 inhibition, both in terms of antitumor activity and activation of the tumor inflammatory microenvironment. Moreover, we've also shown that systemic activity of our masked interferon is significantly reduced, and overall tolerability is markedly improved compared to the unmasked cytokine in animal models. Our phase 1 dose escalation study is now open, and our first clinical site has been activated. This study will evaluate safety and signs of clinical activity for CX-801 as a monotherapy, and in combination with Keytruda, under a collaboration and supply agreement that we recently executed with Merck. We anticipate initial data for CX-801 in the second half of 2025. On the collaboration front, we continue to have more than 10 ongoing research programs with our partners, which include Amgen, Astellas, BMS, Moderna, and Regeneron, with the majority of our partnered research currently focused in masked T-cell engagers. To date, in 2024, we've already achieved $10 million in preclinical milestones through our collaboration with Astellas. Across our collaborations, we have the potential to earn additional milestones over the next 12-18 months and beyond. CytomX also retains significant U.S. commercial rights in certain partnerships, including with Astellas, for a select number of programs, and with Amgen, as part of our global development alliance on CX-904. Partnering continues to be a cornerstone of our business strategy. Before handing over to Chris to cover financials, let me first congratulate him on his promotion to Chief Financial Officer. We're really excited to have Chris's cross-functional leadership and strategic finance experience in this key role, and my colleagues and I look forward to continuing to partner with Chris as we build value in CytomX over the near and long term. With that, let me hand over to Chris to provide an update on our finances. Thank you, Sean. It is a privilege to be part of the CytomX team, and I look forward to helping lead the company towards multiple new treatment options for patients over the long term. Now, turning to the second quarter results, I am pleased to be able to share an update on our financials with everyone today. CytomX finished the second quarter of 2024 with $137 million in cash, cash equivalents, and investments, versus $150 million in cash at the end of the first quarter of 2024. We expect our cash balance will fund the operations of the company to the end of 2025. Also, as a reminder, this cash guidance does not assume any additional milestones from existing collaborations or any new business development. Operationally, we continue to be focused on controlling cost and disciplined capital allocation, investing behind the clinical progression of our lead pipeline programs. Now, moving on to revenue and operating expenses for the quarter. For the second quarter of 2024, revenue was $25.1 million, compared to $24.7 million in the second quarter of 2023. Operating expenses for the second quarter were $33.6 million. R&D expenses were $25.2 million in the second quarter of 2024, an increase of $4.5 million versus Q2 2023, driven by investments in our clinical pipeline. G&A expenses increased by $1 million during the three months ended June 30, 2024 to $8.4 million, compared to $7.4 million for the corresponding period in 2023. Overall, our prudent financial management of the company and focused capital allocation has resulted in continued balance sheet strength and positions us to deliver meaningful value through our pipeline over the next 12-18 months and in the long term. Now I'll turn the call back to Sean for closing remarks. Thanks, Chris, and thanks everyone for joining us today. CytomX has continued to make excellent progress throughout 2024, and we believe the company outlook is very compelling as we drive forward with our multimodality Probody therapeutic pipeline. Our current pipeline reflects broad investments over time and deep learning as a leading innovator in the field of antibody masking and conditional activation. Our progress with CX-904 positions CytomX at the forefront of the exciting field of T-cell engagers for solid tumors, and we, like many others, see this area as being on the cusp of breakthroughs for patients. CytomX continues to prosecute a multimodality strategy with each of CX-904, CX-2051, and CX-801 being well positioned for new clinical data sets over the next 18 months. Moreover, masking strategies, as exemplified by the Probody therapeutic platform, are of growing strategic interest in the biopharma R&D area, and CytomX remains a recognized leader, having created this field. In conclusion, here at CytomX, we remain highly committed and focused on creating innovative treatments for people living with cancer, and we believe our Probody pipeline has the potential to deliver safer, more effective therapies. I want to sincerely thank the patients who join our studies, their families, and our team for helping to drive our mission forward. And with that, operator, let's go ahead and open up the call for Q&A. Thank you. To ask a question, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. One moment for our first question. Our first question will come from the line of Etzer Darout from BMO Capital Markets. Your line is open. ... Great. Thanks for taking the question. Just a quick one on CX-904. If you know, if you've had any more insights into sort of the correlation between efficacy and EGFR expression and what, you know, could be driving the activity that you're seeing in pancreatic cancer. And maybe just remind us for CX-904, can you discuss sort of the venue, if you, if you've kind of given some thoughts into sort of the venue where you'll be presenting this update by year-end? Thanks. Yeah. Hi, so thanks for the questions. So we're continuing to look at EGFR and how it relates to activity for 904. As we, as we've mentioned, you know, pancreatic cancer, like many others, expresses EGFR. More than 90% of pancreatic ductal adenocarcinoma expresses EGFR. So, you know, that clearly relates to the activity that we're seeing, we would think, in that tumor type. As to specific correlations between target level and response, I think that remains to be determined. And I would also say that, of course, for T cell engagers, if we look at historical data from other programs, from other organizations, you know, these agents are quite different to, you know, functional blocking antibodies in that, we wouldn't necessarily expect to require too much antigen to drive responses. But I think this is something we're still learning both for 904 and in the field of T cell engagers more broadly. In terms of, you know, the next update, so yeah, as we mentioned, we're planning on an update by the end of the year. That could take the form of a strategic update in terms of next steps for the program, with actual data that underpins that strategic update, which will of course include a dialogue with Amgen, with that data coming at a future date at a venue to be determined. So, no additional color on that at this time. Great. Thank you. Thank you. One moment for our next question. Our next question comes from the line of Malcolm Kuno from JPM. Your line is open. Hi, thank you for taking the question. This is Malcolm on for Anupam Rama. So you've talked about the scope of the 904 update at the end of the year. How should we think about the size of maybe the data that we may receive? And then, given that you saw a signal earlier this year, how are you thinking about prioritizing indications? Yeah, thanks, Malcolm. So again, with regard to, you know, our goal for an update by the end of this year, you know, our overriding focus in the second half of 2024 is to generate additional data to facilitate strategic dialogue with our partner, Amgen, regarding potential next steps for the program. And the obvious next step, if the data supports it, of course, is to move from phase 1A to phase 1B. So, you know, we're currently enrolling, of course, additional patients in pancreatic cancer to continue to more fully explore that promising initial signal. And so I would say that, you know, as we reach the end of 2024, I would hope that we'd have a reasonable number of patients enrolled in pancreatic to have a much better sense of the overall profile of the activity of the drug in that tumor type. We're also prioritizing enrollment in head and neck and also in non-small cell lung. And in those two indications, yeah, we've really enrolled very few patients when we gave the update in May. And so there, we're looking to enroll additional patients to really look for an initial signal in those two tumor types, and that would be our goal by the end of this year as well. And again, just to be clear, in terms of, you know, our, our overriding objective, generate data, meet with Amgen, have that strategic dialogue, define phase 1B strategy, again, should the data support that. And, most likely give a strategic update on the program by the end of the year with the data that underpins that update, more likely than not, being presented at a venue TBD, in 2025. Great. Thank you so much. You are very welcome. Thank you. Once again, that's star one one for questions. One moment for our next question. Our next question comes from the line of Mitchell Kapoor from H.C. Wainwright. Your line is open. Good afternoon. This is Dan on for Mitch. Thanks for taking our questions, and congratulations on the promotion, Chris. I apologize- Thank you. If my questions are redundant. I, you're welcome. I hopped from another call. We were wondering, given the context of the positive responses you've demonstrated in pancreatic cancer, what response rate or duration of response would be considered meaningful in future updates? Yeah, so regarding... Again, thanks for the question. Regarding pancreatic, I think we're all aware of just how, you know, the dearth of, you know, therapies available for patients after frontline. And, you know, in the second line setting, you're seeing activity of, principally chemo regimens with, you know, single-digit response rates. So, these are patients that are in, you know, tough shape, very few options. And, you know, quite frankly, we think that bar is quite low, you know, unfortunately, given the current state of treatment of pancreatic cancer. So, that's one of the many reasons that we've been really excited about this initial signal in pancreatic, that we're in the midst of firming up with additional enrollment as we move into the second half of the year. ... Awesome. If I could ask a follow-up, do you expect to see any tolerability differences with CX-2051, given the variability in IHC EpCAM expression? I'm sorry, could you repeat the question? Do you expect to see tolerability differences with CX-2051, given the variability in IHC EpCAM expression, and the difference in EpCAM expression between individuals? Well, you know, we're obviously very early in our clinical exploration of CX-2051. We're, you know, very pleased to have, in, you know, very short order already have navigated into the third cohort in the phase 1 dose escalation. And, yeah, we're on track for initial data in first half of next year. EpCAM is to us, a highly attractive target, has been for a long time, because of just how high its expression is in so many tumor types. And its expression is actually pretty consistent, particularly in colorectal, where we're focusing enrollment in phase 1. In CRC, EpCAM has expressed that IHC 3+ in the majority of patients, and that's actually allowing us to not need to select patients, for enrollment in the phase 1 study. So, in terms of the expression in normal tissues, yeah, there's a fair amount of EpCAM in normal tissues, particularly in, also in the GI tract. It can be heterogeneous, but I think we'll have to see how that plays out in the clinic. But so, yeah, so far, so good as we're into our third cohort. Awesome. Thank you so much. You're welcome. Thank you. I'm not showing any further questions in the queue. I would now like to turn it back over to Dr. Sean McCarthy, Chairman and CEO, for closing remarks. Thanks very much, and thanks everyone for tuning in today. We're really excited about the progress we've made so far this year at CytomX, and we're looking forward to a busy second half and to reporting on additional progress as the year goes on. So, have a great rest of the day. Thank you for your participation in today's conference. This does conclude the program. You may now disconnect. Everyone, have a great day.